Review Article

Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors

Chunkit Fung,1 Paul Dinh Jr.,2 Shirin Ardeshir-Rouhani-Fard,2 Kerry Schaffer,3 Sophie D. Fossa,3 and Lois B. Travis2

1James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA
2Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN, USA
3Department of Oncology, Oslo University Hospital, Radium Hospital, Oslo, Norway

Correspondence should be addressed to Chunkit Fung; chunkit_fung@urmc.rochester.edu

Received 29 August 2017; Accepted 6 December 2017; Published 18 February 2018

1.Introduction

Testicular cancer (TC) is the most common cancer, affecting young men aged 18–39 years [1]. Due to effective cisplatin-based chemotherapy introduced in the 1970s [2], TC is highly curable with a 10-year relative survival approaching 95% [3, 4]. However, treatment-related complications, including cardiovascular disease (CVD), second malignant neoplasms (SMN), neuro- and otoxicity, pulmonary complications, nephrotoxicity, hypogonadism, infertility, avascular necrosis, cognitive impairment, anxiety/depression, and chronic cancer-related fatigue, accompany these remarkable successes [5–7]. These adverse outcomes of TC and its therapy have emerged as important issues for this young cohort of survivors. In this review article, we will focus on toxicities due to cisplatin-based chemotherapy and radiotherapy experienced by long-term survivors of TC, which are defined as individuals who are disease-free 5 years or more after primary treatment [8]. Due to sparse data, the risks of long-term toxicities after single-dose carboplatin for stage I seminoma or one to two cycles of bleomycin, etoposide, and cisplatin (BEP) for stage I nonseminoma will not be reviewed.

2. Cardiovascular Disease and Raynaud Phenomenon

A few hypotheses have been proposed to explain the pathophysiology of CVD in TC survivors (TCS), including the direct vascular damage hypothesis, the indirect hypothesis, and more recently the multiple-hit hypothesis [9, 10]. The direct vascular damage hypothesis proposes that cisplatin-based chemotherapy causes direct damage to the vascular endothelium [9]. In vitro exposure of endothelial cells to cisplatin or bleomycin causes cytokine release and cytotoxicity [11, 12]. Von Willebrand factor, an inflammatory...
marker released by endothelial cells in response to vascular
damage, increases in TC patients during chemotherapy [13].
Other markers of inflammation and endothelial dysfunction
are also evident after cisplatin-based chemotherapy,
including fibrinogen, tissue-type plasminogen activator, and
high-sensitivity C-reactive protein [14, 15]. Microalbuminuria
is present in an increased number of TC patients treated
with cisplatin-based chemotherapy [14, 16], which is a clinical
manifestation of systemic vascular dysfunction that
independently predicts for vascular events, including stroke
and myocardial infarction (MI) [17]. In one study, micro-
albuminuria persisted in 22% of TCs treated with cisplatin-
based chemotherapy after a median follow-up of 14 years [16].

A prior investigation [15] showed that the carotid intimal
medial thickness of TC patients, which correlates with
increased risk of cerebrovascular accidents and MI [18], sig-
nificantly increased during a 3.5-month course of cisplatin-
based chemotherapy. This rate of increase was significantly
higher than the annual change observed in carotid intimal
medial thickness in the general population. Acute alterations
in diastolic heart function were reported in a study [19] of
14 TC patients three months after initiation of 3 to 4 cycles
of chemotherapy with BEP; these included significant de-
creases in the left ventricular end-diastolic and stroke vol-
umes. Other suggested mechanisms of direct vascular
damage include cisplatin-induced vasospasm due to hypo-
magnesemia [20–23] and increased formation of procoa-
gulant endothelial microparticles released by endothelial
cells, triggering thrombin generation and hypercoagulability
[24, 25].

Raynaud phenomenon is another clinical manifestation
of vascular damage and is estimated to be present in ap-
proximately 25% to 61% of TCs [26–30]. The onset of symp-
toms from Raynaud phenomenon generally begins within 4
to 12 months of chemotherapy, with 25% experiencing these
symptoms up to 20 years [14]. Bleomycin is strongly asso-
ciated with the development of Raynaud phenomenon. In a
randomized study [31] of 395 patients with good-risk me-
tastatic nonseminoma, 8% of patients randomized to BEP
developed Raynaud phenomenon compared to none under-
going etoposide and cisplatin (EP). Vinblastine and cisplatin
are other chemotherapeutic agents that may contribute to
this toxicity [28–30, 32].

The indirect hypothesis postulates that cisplatin-based
chemotherapy increases the prevalence of CVD risk factors
in TCs, resulting in increased CVD events [9]. Multiple
studies [14, 16, 30, 33–40] have reported increased frequency
of hyperlipidemia, hypertension, diabetes, insulin resistance,
and metabolic syndrome among TC patients after treatment
with chemotherapy compared to surgery-only comparison
groups or controls derived from the general population
(Table 1). Although several studies [36, 38, 41] showed that
metabolic syndrome and its individual components are
associated with testosterone deficiency and hypogonadism,
most TCs with CVD risk factors have normal testosterone
levels [33]. Decreased testosterone levels may cause endo-
thelial dysfunction, impair vascular smooth muscle re-
activity, increase intima and media thickness of vessels, and
increase synthesis of proinflammatory cytokines [42–44].

In an investigation by Haugnes et al. [33], relationships with
both hypogonadism and cumulative dose of cisplatin and
metabolic syndrome were evaluated among 1135 Norwegian
TCs. Compared to the surgery group, TCs who received a
cumulative dose of cisplatin >850 mg had a significant 2.8-
fold increased odds of metabolic syndrome, with both total
serum testosterone and smoking history (≥20 pack-years)
being independent predictive factors in multiple regression
models.

A multiple-hit hypothesis that encompasses both the
direct and indirect hypotheses has recently been proposed
to explain the elevated risk of CVD among TCs [10, 45].
This model hypothesizes that multiple factors interact
synergistically to increase the risks of CVD among TCs,
including orchiectomy-derived subclinical hypogonadism,
chemotherapy-induced vascular injury, chemotherapy-
related disturbance of metabolic homeostasis, and other
TC treatment-related toxicities [10].

The relative risk of CVD among TCs treated with
chemotherapy is 1.4- to 7.1-fold significantly higher com-
pared to the general population or to those managed with
surveillance only [16, 34, 35, 46, 47]. A British study [35] of
390 TCs treated with chemotherapy between 1982 and 1992
at a median follow-up of 9.7 years showed a 7% incidence of
angina, MI or sudden cardiac death, with an elevated age-
adjusted relative risk (RR) of 2.6 (95% confidence interval
(CI) 1.2–5.8) when compared with TC patients treated with
surgery alone. In a retrospective study [46] of a nationwide
cohort of 2707 5-year TCs in the Netherlands (1965–1995)
after a median follow-up of 17.6 years, cisplatin-based che-
motherapy (cisplatin, vinblastine, bleomycin (PVB) or BEP)
increased the risk of CVD by 1.7-fold (95% CI 1.1–2.5) when
compared with age and sex-matched data in the general
Dutch population.

To determine CVD risk after modern-era cisplatin-based
chemotherapy in TC patients, Haugnes et al. [34] evaluated
the prevalence of cardiovascular risk factors and long-term
incidence of CVD among 990 5-year TC survivors (median
follow-up: 19 years). All cytotoxic treatment groups (radi-
ation only, chemotherapy only, and combined radiation/
chemotherapy) had significantly increased prevalence of
usage of antihypertensive medications compared with age-
matched male controls in the general population. The odds
diabetes were higher in the radiation (odds ratio (OR) 2.3;
95% CI 1.5–3.7) and radiation/chemotherapy groups (OR 3.9;
95% CI 1.4–10.9) compared to controls [34]. Using age-
adjusted Cox regression analyses, increased risks of athero-
sclerotic disease were reported in the radiation only (hazard
ratio (HR) 2.3; 95% CI 1.04–5.3), chemotherapy only (HR
2.6; 95% CI 1.1–5.9), and combined radiation/chemotherapy
cohorts (HR 4.8; 95% CI 1.6–14.4) compared to those
managed with surgery only [34]. Treatment with BEP alone
increased the risk of coronary artery disease by 5.7-fold (95%
CI 1.9–17.1) compared with surgery only, while the risk for
MI increased by 3.1-fold (95% CI 1.2–7.7) compared with
age-matched male controls [34].

Using age-adjusted Cox regression analyses, increased
risks of atherosclerotic disease were reported after radiation
only (HR 2.3; 95% CI 1.04–5.3), chemotherapy only (HR 2.6;
Table 1: Prevalence of cardiovascular disease risk factors in chemotherapy-treated patients in select studies since 2000.

| Author (year)            | N  | Treatment dates | Median length of follow-up (range) | Median age at follow-up (range) | Control group (N) | HTN (definition) | Increased lipids (definition) | DM (definition) | Obesity (definition) | Metabolic syndrome (definition) |
|--------------------------|----|-----------------|-----------------------------------|---------------------------------|-------------------|-----------------|-------------------------------|----------------|---------------------|------------------------------|
| Meinardi et al. (2000)   | 62 | Before 1987     | 14 y (10–20 y)                    | 42 y (30–50 y)                  | Stage I TC (40)   | 39 versus 13 (SBP > 150 mmHg, DBP > 95 mmHg) | 79 versus 53 (TC ≥ 201 mg/dL) | NA             | 21 versus 28d (BMI ≥ 27.8) | NA                           |
| Strumberg et al. (2002)  | 32 | 1977–1981       | 15 y (13–17 y)                    | 40 y (30–59 y)                  | None              | 25 versus NA (DBP > 95 mmHg) | 81 versus NA (TC ≥ 200 mg/dL) | NA             | 48 versus NA (BMI ≥ 25) | NA                           |
| Huddart et al. (2003)    | 390| 1982–1992       | 10 y (0–20 y)                     | 41 y (23–72 y)                  | Stage I TC (242)  | 13 versus 9d (antihypertension medication) | 1 versus 2d (lipid-lowering medication) | NA             | NA                  | NA                           |
| Nuver et al. (2004)      | 90 | 1988–1999       | 7 y (NA)                          | 37 y (20–65 y)                  | Stage I TC (44) and healthy patients (47) | 22 versus 23 versus 11d (SBP ≥ 135 mmHg, DBP ≥ 85 mmHg) | 71 versus 59 versus 45e (LDL > 131 mg/dL) | NA             | 22 versus 27 versus 11e (BMI ≥ 30) | NA                           |
| Nuver et al. (2005)      | 86 | 1988–1999       | 7 y (3–13 y)                      | 37 y (20–65 y)                  | Stage I TC (44) and healthy patients (47) | NA               | NA                           | NA             | NA                  | NA                           |
| Sagstuen et al. (2005)   | 500| 1980–1994       | 11 y (4–22 y)                     | 44 y (23–75 y)                  | Surgery-onlyf (242) | 50 versus 39 (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or antihypertension medication) | NA             | 18 versus 13h (BMI ≥ 30) | NA                           |
| Haugnes et al. (2007)    | 464| 1980–1994       | 11 y (5–22 y)                     | 43 y (15–52 y)                  | Surgery-onlyf (225) and healthy population (1150) | 45 versus 34 versus 50f (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or antihypertension medication) | 68 versus 67 versus 84d (TC ≥ 201 mg/dL) | 3 versus 2 versus 3d (by patient self-report) | 18 versus 13 versus 21d (BMI ≥ 30) | 9 versus 7 versus 15h (≥3 factors per NCEP definition [163]) |
| Haugnes et al. (2010)    | 364| 1980–1994       | 19 y (13–28 y)                    | 49 y (31–69 y)                  | Surgery-onlyf (206) and healthy population (990) | 26 versus 12 versus 13 (antihypertension medication) | 14 versus 14 versus 9e (lipid-lowering medication) | 5 versus 4 versus 4d (by patient self-report or fasting glucose ≥ 198 mg/dL) | 17 versus 19 versus 23d (BMI ≥ 30) | NA                           |
Table 1: Continued.

| Author (year)       | N<sup>a</sup> | Treatment dates | Median length of follow-up (range) | Median age at follow-up (range) | Control group (N) | HTN (definition) | Increased lipid<sup>c</sup> (definition) | DM (definition) | Obesity (definition) | Metabolic syndrome (definition) |
|---------------------|--------------|-----------------|------------------------------------|---------------------------------|-------------------|-----------------|-------------------------------------------|-----------------|---------------------|-------------------------------|
| Willems et al. (2013) [38] | 194<sup>†</sup> | 1977–2008       | 7.8 y (0.1–30 y)                   | 39.6 y (18–70 y)                | Surgery-only (57) and healthy population (360) | 29 versus 14 versus 22.5<sup>k</sup> (per NCEP definition [163]) | NA | NA | 29 versus 18 versus 19<sup>k</sup> (per NCEP definition [163]) |
| de Haas et al. (2013) [39] | 173<sup>†</sup> | 1977–2004       | 5 y (3–20 y)                       | 37 y (19–59 y)                  | Healthy population (1085) | 59 versus NA (SBP ≥ 130 mmHg or DBP ≥ 85 mmHg or antihypertension medication) (AHA/NHLBI definition) | 44 versus NA (HDL < 1.03 mmol/l or lipid-lowering medication) (AHA/NHLBI definition) | 14 versus NA (fasting glucose ≥ 5.6 mmol/l or medication) (AHA/NHLBI definition) | 17 versus NA (waist circumference ≥ 102 cm) (AHA/NHLBI definition) | 25 versus NA (≥ 3 factors per AHA/NHLBI definition) |
| Fung et al. (2017) [40] | 952<sup>‡</sup> | 1979–2015       | 4.3 y (1.0–29.9)                   | 37 y (19–68 y)                  | NHANES matched controls (952) | 16.8 versus 19.4<sup>d</sup> ever diagnosed with high blood pressure and current use of antihypertension medication | 10.5 versus NA<sup>†</sup> current use of cholesterol lowering medication | 3.1 versus NA<sup>†</sup> diabetes requiring insulin or diabetes requiring medication | 31.3 versus 35.4<sup>†</sup> BMI ≥ 30 | NA |

<sup>a</sup>Adapted with permission from Feldman et al. [9] (Table 2). AHA: American Heart Association; BMI: body mass index; DBP: diastolic blood pressure; DM: diabetes mellitus; NHLBI: National Heart, Lung, and Blood Institute; NHANES: National Health and Nutrition Examination Survey; TC: testicular cancer; HTN: hypertension; LDL: low-density lipoprotein; NA: not available; NCEP: National Cholesterol Education Program; SBP: systolic blood pressure; TC: total cholesterol. (a) N varies slightly for individual factors due to missing data in papers for some variables. (b) Definitions of individual factors vary by study. Comparisons of chemotherapy groups to controls significant unless otherwise stated; percentages vary slightly due to missing data for individual factors. (c) Cholesterol and fasting glucose values in definitions were converted from mmol/L to mg/dL, where necessary for uniformity. (d) Not significant. (e) Significant versus healthy population controls but not versus surgery patients. (f) Includes both orchiectomy and primary retroperitoneal lymph node dissection patients. (g) A healthy population control group was also included in this study, but prevalence rates of cardiovascular risk factors were not reported for this control group, and therefore these data are not included in the table. (h) Significant only for patients who received >850 mg of cisplatin. (i) Significant versus surgery patients but not versus healthy controls. (j) 20 patients received carboplatin and 174 patients received combination chemotherapy. (k) Significant for patients who received combination chemotherapy compared to healthy population. (l) Significance versus controls not tested.
Second cancers: etiology

Cancer #1
- Treatment
- Cancer #2
- Lifestyle
  - Tobacco
  - Alcohol
  - Diet
- Environment
  - Contaminants
  - Occupation
- Host factors
  - Genetics
  - Immune function
- Interactions and other influences
  - Including gene-environment

Figure 1: Risk factors for second primary cancer (refer to text). Many influences some of which are diagrammed here may contribute to the development of multiple primary cancers, including interactions between exposures. *Adapted with permission from Travis [169].

After receiving radiotherapy for TC treatment, TCS have significantly increased risks of leukemia [56] and solid cancers [46, 55, 57–59] (Table 2). An international population-based study of 18,567 TCS reported a significantly 3-fold increased risk of leukemia after abdominal and pelvic radiotherapy with a mean dose of 10.9 Gy to active bone marrow [56]. The median latency for leukemia was 5.0 years with a quarter of survivors developing leukemia more than one decade later (maximum latency: 17.3 years) [56]. After radiation treatment, long-term TCS also have significantly 1.4 to 1.9-fold increased risks of second solid cancers compared to the general population (Table 2) [46, 55, 57]. An international population-based investigation of 10-year TCS reported that the RR of SMN at sites included in typical infradiaphragmatic radiotherapy fields were significantly larger than risks at unexposed sites (RR 2.7 versus 1.6; \( P < 0.05 \)) which remained elevated for more than 35 years. In another study [46], infradiaphragmatic radiotherapy administered at doses 40–50 Gray (Gy) compared with 26–35 Gy increased the HR for SMN from 2.3 to 3.2, respectively, when using a surgery-only group as control. Two recent studies of 5-year TCS reported a 5.9-fold increased risk of stomach cancer (95% CI 1.7–20.7) [58] and a 2.9-fold increased risk of pancreatic cancer (95% CI 1.0–7.8) after radiotherapy [59]. The risks of stomach and pancreatic cancers increased with higher radiation doses to stomach [58] and pancreas [59], respectively (\( P \) trend < 0.001), and risks remained elevated for ≥20 years after exposure (\( P < 0.01 \)) [58, 59]. Several other studies of TCS [46, 60, 61] similarly reported significant associations between radiotherapy and SMN risks.

Cisplatin and etoposide are integral chemotherapeutic agents used in standard chemotherapy regimens to treat TC [62]. Both cisplatin and etoposide are associated with significantly elevated risks of secondary leukemia [56, 63–65]. An international nested case-control study [56] among TCS estimated a 3.2-fold risk of leukemia after cumulative cisplatin dose of 650 mg, although the excess risk was small with only 16 excess cases among 10,000 TC patients after 15 years of follow-up. The same study also reported a significant dose-response relationship between cumulative dose of cisplatin and leukemia risk after adjustment for radiation dose.
The 5-year cumulative incidence of leukemia is approximately 0.5% after a cumulative etoposide dose of <2000 mg/m² and 2.0% after a cumulative etoposide dose of ≥2000 mg/m² [65].

Most prior studies of second solid cancer focused on TCS treated before modern cisplatin-based chemotherapy became widely adopted prior to early 1980s (Table 2) [10, 13, 22, 23]. Whereas an international series of more than 40,000 TCS showed a 1.8-fold (95% CI 1.3–2.5) significantly increased risk of second solid cancers among a subgroup of 10-year TCS who received initial chemotherapy during 1943–2001, three smaller epidemiologic studies [10, 39, 57] (ranging from 346 to 710 patients) found no significantly elevated risk of SMN after chemotherapy [27, 46, 66], though they may have inadequate statistical power. To evaluate the risks of second solid cancer among TCS treated in the modern era of cisplatin-based chemotherapy during 1980 to 2008, a recent large population-based investigation by Fung et al. [67] of more than 12,000 TCS reported a 1.4-fold significantly increased risk of solid cancers after initial treatment with chemotherapy compared to those who underwent initial surgery alone. Significantly increased three- to seven-fold risks of cancers of the kidney (SIR 3.4), thyroid (SIR 4.4), and soft tissue (SIR 7.5) were also observed. After chemotherapy, elevated risks of solid cancer were reported in most follow-up periods.
with a median latency of 12.5 years, including at more than 20 years after treatment (SIR 1.54; 95% CI 0.96–2.3). However, detailed information on cytotoxic drug name and dose were not available [67].

TCS should follow national guidelines for cancer screening as applied to the general population, given their increased risks of SMN [53]. Earlier or additional cancer screening may be clinically indicated in TCS deemed at high risk due to prior treatment history and/or health habits [53]. In addition, health care providers should advise TCS of the modest 15-year cumulative risk (1.9%) of metachronous contralateral testicular cancer [68].

4. Neurotoxicity

Approximately 20 to 40% of long-term TCS experience symptoms of peripheral neuropathy after cisplatin-based chemotherapy [28, 29, 69]. Common clinical manifestations of peripheral neuropathy include numbness, tingling, and a decrease in vibratory sense in distal extremities [70]. The cumulative dose of cisplatin administered affects the incidence of peripheral neuropathy. At a median of 11 years after TC treatment, 46% of TCS in a population-based long-term Norwegian survey self-reported paresthesia after ≥5 cycles of cisplatin-based chemotherapy compared to 28% after 1 to 4 cycles of chemotherapy or 10% after orchectomy alone [28]. Compared to TCS who did not receive chemotherapy, those who underwent 1 to 4 cycles and ≥5 cycles of cisplatin-based chemotherapy had higher risks of symptomatic paresthesia of the hands (OR 2.0, 95% CI 1.5–2.7; OR 3.9, 95% CI 2.1–7.3, resp.) and feet (OR 2.2, 95% CI 1.7–3.0; OR 3.1, 95% CI 1.7–5.7, resp.) [28]. In the same study [28], radiotherapy was significantly associated with symptomatic paresthesias of the feet (OR 1.5), but retroperitoneal lymph node dissection (RPLND) was not an independent risk factor. Increasing levels of residual serum platinum are also directly associated with severity of neurotoxicity after adjusting for initial cisplatin dose [71]. Sprauten et al. reported [71] that the total score for the Scale for Chemotherapy Induced Neuropathy (SCIN) had a significant four-to five-fold association with the highest residual serum platinum quartile in cisplatin-treated TC patients.

Oldenburg et al. [72] investigated the impact of germ-line single nucleotide polymorphisms (SNPs) of glutathione S-transferase (GST) PI, M1, and T1 on self-reported paresthesia among long-term TCS. The GSTP1-GG genotype conferred a significantly lower risk of developing paresthesia in the fingers (OR = 0.46, 95% CI 0.22–0.96) and toes (OR = 0.42, 95% CI 0.20–0.88) than the GSTP1-AA and GSTP1-AG genotypes. Recently, a genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer reported that genetically determined expression level of RPRD1B was associated with cisplatin-induced peripheral neuropathy [73]. Defects in RPRD1B expression or knockdown cause a deficiency in DNA repair mechanisms known to be critical in repairing cisplatin-induced lesions [74] and result in increased sensitivity to cisplatin in a breast cancer cell line, MDA-123 [75].

No therapeutic agents are currently recommended for the prevention of peripheral neuropathy due to the paucity of high-quality, consistent evidence. For management of drug-induced peripheral neuropathy, the ASCO Clinical Practice Guideline [76] recommends treatment with duloxetine as potentially the most effective drug. Health care providers may also offer tricyclic antidepressants (i.e., nortriptyline), gabapentin, and a compounded topical gel containing baclofen, amitriptyline HCL, and ketamine based on clinical benefits observed for other neuropathic pain conditions [76].

5. Ototoxicity

Cisplatin selectively damages the outer hair cells of the cochlea [77], causing tinnitus and hearing loss that predominantly affect high frequencies [77–79] similar to age-related presbycusis. After a median follow-up of 58 months, Bokemeyer et al. [78] found that 20% of TCS (median age: 31 years) reported symptomatic ototoxicity (59% tinnitus, 18% hearing loss, 23% both) after cisplatin-based chemotherapy. For TCS who received >400 mg/m² of cumulative cisplatin dose, 50% self-reported tinnitus and hearing loss compared to 20% of those treated with ≤400 mg/m² [78].

Older age, higher cumulative cisplatin dose, a history of noise exposure, hypertension, and impaired baseline renal function and hearing are each independently associated with more severe ototoxicity [78–80]. A recent comprehensive audiometric analysis of 488 North American TCS [79] reported that almost one in five (18%) had severe to profound hearing loss as defined by the American Speech-Language-Hearing Association criteria (median follow-up: 4.25 years after completion of cisplatin-based chemotherapy). Tinnitus (40% patients) was significantly correlated with reduced hearing at each frequency (P < 0.001). The same study [79] also found that increasing cumulative cisplatin dose was significantly related to hearing loss at 4, 6, 8, 10, and 12 kHz (P trend for each <0.05). For each 100 mg/m² [2] increase in cumulative cisplatin dose, a 3.2 dB impairment in age-adjusted overall hearing threshold (4–12 kHz; P < 0.001) resulted. However, cisplatin dose did not affect noise-induced hearing damage (10% patients) (P = 0.59) [79].

A few reports have identified significant associations of germline genetic polymorphisms of various genes with platinum-related ototoxicity, including megalin [81], GSTP1 [72, 82], GSTM3 [72, 82], COMT [83], TPMT [83], and WFS1 [84]. Both alleles of 105Val-GSTP1 protected against cisplatin-induced ototoxicity in cisplatin-treated TCS, whereas GSTM1 positivity was detrimental for hearing ability [82]. Functional polymorphisms of the glutathione S-transferases (GSTs) genes likely cause differential expression of the cisplatin-detoxifying enzymes, consequently rendering TCS susceptible to varying degrees of cisplatin-induced hearing impairment. A recent genome-wide association study [85] of 511 TC patients of European genetic ancestry reported that one SNP, rs62283056, in the first intron of WFS1 (wolfamin ER transmembrane glycoprotein) was significantly associated with cisplatin-associated ototoxicity (P = 1.4 × 10⁻⁶), with higher cisplatin doses exacerbating
hearing loss in TC patients with the risk allele. In the general population, WSF1 mutations cause the Mendelian disorders DFNA6 (deafness, autosomal dominant 6) and the recessive Wolfram syndrome (with hearing loss) [86, 87].

There are no effective pharmacologic agents available to prevent or treat cisplatin-induced ototoxicity. TCS should use ear protection to minimize noise exposure and additional hearing loss. Since the peak concentration of cisplatin may be directly associated with the severity of ototoxicity [28, 88], where indicated, the 5-day BEP regimen seems preferable to a 3-day regimen [7].

6. Pulmonary Toxicity

The incidence of fatal bleomycin-induced pulmonary toxicity is approximately 1–3% [89, 90]. Corticosteroids remain the mainstay of treatment of bleomycin-induced pneumonitis, although there are no data from prospective randomized trials to support this approach [91]. Health care providers should withhold bleomycin at the earliest signs or symptoms of bleomycin-induced pulmonary toxicities during chemotherapy. Since age of more than 40 years [89] and increased tobacco use [92] are both significantly associated with pulmonary toxicity during bleomycin treatment, a careful assessment of patient history (i.e., age, smoking status, and preexisting lung disease) are important to consider prior to the administration of any bleomycin-containing regimen [93]. Avoiding perioperative overhydration is important to minimize the risk of perioperative lung complications, but perioperative oxygen restriction in patients a few months after administration of bleomycin is not necessary [94, 95].

Bleomycin hydrolase is an enzyme encoded by the BLHM gene, which inactivates bleomycin [96]. A Dutch investigation of 340 TC patients treated with bleomycin-containing chemotherapy between 1977 and 2003 reported that the genetic polymorphism of 1450A>G was not associated with bleomycin-induced pneumonitis or changes in pulmonary function tests [97].

A large Norwegian study [92] of 1049 long-term TCS treated during 1980 to 1994 (median follow-up: 11.2 years) reported that 8% of survivors had restrictive lung disease as defined by predicted FVC <80% and a value of ≥70% for forced expiratory volume (FEV) 1/forced vital capacity (FVC). In multivariate analyses adjusting for bleomycin, etoposide, and vinblastine doses, higher cumulative cisplatin dose (P = 0.007) and older age (P = 0.008) were both significantly related to restrictive lung disease [92]. Compared with men treated with surgery only, patients who received large cumulative doses of cisplatin (>850 mg) as well as combined chemotherapy and pulmonary surgery were at significantly increased risk of demonstrating decreased spirometry variables, including age-adjusted FVC, FEV1, FVC%, predicted, and FEV1% predicted [92]. A population-based study of TCS reported to North American and European cancer registries found that patients treated with chemotherapy (with or without radiotherapy) in 1975 or later had a 1.6-fold higher risk of mortality (95% CI 1.25–2.01) (median follow-up: 10 years) due to respiratory diseases compared to the general population. The extent to which bleomycin-induced lung toxicity may have contributed to these excesses is not known.

7. Nephrotoxicity

Cisplatin damages the proximal and distal renal tubular epithelium and the renal collecting duct system, as well as the glomeruli at higher doses [98, 99]. Two long-term studies [100, 101] reported persistently decreased renal function in TCS for years after completion of treatment compared with baseline assessments. A Norwegian study [100] of 85 TC patients more than 10 years after treatment showed that renal function among TCS who received radiotherapy alone decreased by 8%, whereas survivors who had cisplatin-based chemotherapy had reductions of 14%. Cumulative cisplatin dose and age at treatment were both directly associated with long-term impairment of renal function (P < 0.05). A Danish investigation [101] of 34 TCS who received systemic chemotherapy with PVB (median dose of cisplatin: 583 mg/m²) reported that the glomerular filtration rate (GFR) decreased by a median of 18% during treatment. At a median follow-up of 65 months (range, 43 to 97 months), 38% of survivors had persistent renal dysfunction. Research in the general population has demonstrated a relationship between decreased GFR and the presence of microalbuminuria, leading to increased risks of CVD and all-cause mortality [102, 103]. Among long-term TCS, treatment-related nephrotoxicity may contribute to the reported increases in incident CVD events, including hypertension and MI [34, 35, 47]. To limit the severity of acute- and long-term renal damage, health care providers should administer hydration [104] and avoid nephrotoxic drugs [7] during cisplatin-based chemotherapy.

8. Hypogonadism

Orchietomy, testicular dysgenesis syndrome, postorchiectomy chemotherapy or radiotherapy, and aging are the predominant causes of hypogonadism and premature hormonal aging in long-term TCS [105]. A Norwegian investigation [105] reported that 307 TCS treated between 1980 and 1994 had significantly increased risks of low testosterone as well as high-luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels after radiotherapy or chemotherapy at long-term follow-up. The degree of hypogonadism was directly related to the intensity of TC treatment [105–110]. A recent meta-analysis reported that both standard cisplatin-based chemotherapy (OR: 1.8) and intra-diaphragmatic radiotherapy (OR: 1.6) significantly increased the risk of hypogonadism among TCS, as defined by total testosterone levels less than reference levels or use of testosterone replacement therapy, when compared to orchietomy alone [110]. Hypogonadism may lead to reduced sexual functioning and well-being, fertility problems, muscle weakness, osteoporosis, loss of energy, and depression [111–117]. Further, hypogonadism is directly associated with the metabolic syndrome and CVD [29, 30, 32]. A recent multi-institutional cross-sectional study [118] reported that
Advances in Urology 9

of difficult cases should also be considered. Referral to endocrinologists for evaluation and management dedicated. Clinical symptoms of hypogonadism should guide hypogonadism and check hormonal status as clinically indicated. Clinical symptoms of hypogonadism should guide treatment decisions with testosterone replacement therapy [7]. Referral to endocrinologists for evaluation and management of difficult cases should also be considered.

9. Infertility

The association of infertility and TC is well established. Approximately 50% of patients with newly diagnosed TC have decreased sperm counts (<20 million/mL), low sperm motility indices (<40), and a high percentage of abnormal sperm cells (>80%) prior to initiation of any radiation or chemotherapy [119]. In a multicenter prospective study of 2318 TC patients in Germany and Austria [120], TC patients had significantly reduced spermatogenesis in their contralateral testicles confirmed histologically when compared to healthy subjects. The overall conception and pregnancy rates among long-term TCs with known intention to conceive a child after treatment completion range from 49% to 88% in several investigations (range of median follow-up: 7 to 12 years) [109, 121–123].

Radiotherapy can adversely affect reproductive function of TCs in the short-term [124, 125], since spermatogenesis are the most sensitive germ cells to radiation treatment [126]. In the SWOG-8711 clinical trial of 207 patients with seminoma [124], sperm concentration reached a nadir 4 to 6 months after completion of radiotherapy, but returned to pretreatment level by 10 to 24 months after end of treatment. Similarly, Gandini et al. [127] reported that the sperm counts of TC patients reached a nadir at 6 months after radiation treatment, but 94% of patients recovered sperm counts by 2 years after end of radiotherapy. Higher dose of radiation is directly associated with longer recovery time for sperm concentration, and the use of testicular shielding devices significantly improves recovery of spermatogenesis [124]. A recent investigation of 1191 Norwegian TCs (median follow-up: 11 years) confirmed that radiotherapy had no significant long-term effects on sperm counts when compared to the surgery-only cohort [125].

In a retrospective study [128] of 178 TC patients treated with cisplatin-based chemotherapy in England, 64%, 24%, and 15% of patients who were normospermic, oligospermic and azoospermic, respectively, in the prechemotherapy period recovered normal spermatogenesis at least one year after chemotherapy completion. Prechemotherapy normospermia (HR 6.0), use of carboplatin versus cisplatin (HR 4.4), and noninclusion of a vinca alkaloid (HR 5.3) in chemotherapy regimen were significantly associated with normal recovery of sperm counts [128]. Cumulative dose of cisplatin-based chemotherapy is directly associated with infertility risk [112, 123, 125, 128]. In a multicenter investigation [123] of 316 Norwegian TCs (median follow-up: 12 years), 100%, 83%, and 76% of survivors self-reported achieving posttreatment paternity after 2, 3, and 4 cycles of standard cisplatin-based chemotherapy, respectively (P = 0.022). However, sperm counts were not significantly related to number of cycles of chemotherapy in a limited cohort of patients for whom the results of semen analysis were available (N = 71) [123]. After a median follow-up of 10.6 years, another study [112] showed that TCs treated with high-dose chemotherapy (>850 mg cumulative cisplatin dose) had the lowest 15-year actuarial posttreatment paternity rate (48%) compared to 92% in the surveillance group and 60% in those treated with low-dose chemotherapy (≤850 mg cumulative cisplatin) (P < 0.001). Similarly, a recent investigation [125] reported that sperm counts and serum level of inhibin B were significantly lower in TCs treated with >850 mg cumulative cisplatin dose compared to those who had either surgery only or ≤850 mg cumulative cisplatin, whereas the serum FSH was significantly higher.

Among patients with stage II or III nonseminomatous germ cell tumor who have had a serologic complete response but have persistent enlarged retroperitoneal lymph nodes after cisplatin-based chemotherapy, RPLND is a standard treatment. To potentially avoid toxicities associated with cisplatin-based chemotherapy, RPLND is another treatment option for low-volume stage II nonseminomatous germ cell tumor with normal β-hCG and AFP levels after orchiectomy [62]. Injury to the retroperitoneal postganglionic sympathetic nerves during RPLND may result in retrograde ejaculation [126], leading to inability to conceive without use of cryopreserved sperm. The rate of retrograde ejaculation ranges from 1 to 9% after primary RPLND [129–131], 11% to 29% after nerve-sparing postchemotherapy RPLND [130, 132–134], and 75% after full bilateral postchemotherapy RPLND [135].

Health care providers should address the possibility of infertility and discuss fertility preservation options with TC patients as detailed by the American Society of Clinical Oncology Clinical Practice Guideline for fertility preservation for patients with cancer [136]. If clinically indicated, referral to appropriate reproductive specialists should be considered [136]. Sperm cryopreservation is a standard fertility preservation practice [136] that may be offered to interested TC patients undergoing treatment.

10. Avascular Necrosis

Avascular necrosis commonly affects the femoral head, often bilaterally [137], with an incidence of approximately 1-2% in long-term TCs treated with cisplatin-based chemotherapy [137, 138]. The etiology for avascular necrosis is multifactorial [7] but likely to be partially attributable to corticosteroids used as antiemetics during TC treatment [137–140]. Bleomycin and vinblastine have also been hypothesized as causative agents in a case of avascular necrosis in one TCs who did not receive corticosteroids during chemotherapy [141]. Health care providers should review with TC patients who receive high-dose corticosteroids the potential risk of avascular necrosis. For any long-term TCs who develops early symptoms suggestive of avascular necrosis, including
11. Cognitive Impairment

The underlying mechanisms of chemotherapy-related cognitive impairment have not been elucidated. Several neuroimaging studies of breast cancer survivors have reported that white matter activation patterns involved in cognitive functioning are altered after chemotherapy [142–144], likely due to neurotoxic effects [145]. A study [146] of 66 TC patients suggested that cortisol levels prior to chemotherapy may be a predictor of later cognitive complaints. The prevalence of cognitive impairment in men with newly diagnosed TC before receipt of any chemotherapy ranges from 46% to 58% and is significantly higher than expected in the healthy normal population (P < 0.01) [146, 147]. A prospective clinical trial [88] of 666 patients with metastatic TC in Europe showed that cognitive function decreased at 3 months after chemotherapy, though not at the level of clinical relevance but recovered to baseline values at 2 years for most patients, with 19% still having worsened cognitive function at that time. However, the association of cisplatin-based chemotherapy with cognitive impairment in TCS remains unclear. Whereas three studies [148–150] of TCS (N = 70–112; median follow-up: 1–3 years) reported no significant differences in performance on cognitive tests between TC treatment groups (i.e., surgery only versus chemotherapy), two investigations [151, 152] reported increased risks of cognitive impairment after chemotherapy. Among 1173 TCS with a median follow-up of 9 years, Skoogh et al. [151] reported a 2-fold increased risk (95% CI 1.3–3.1) of long-term compromised speech in survivors who completed five or more cycles of cisplatin-based chemotherapy compared to those who received no chemotherapy. Similarly, a single institutional prospective study [152] of TC patients after orchietomy who either received adjuvant chemotherapy (N = 55) or no additional treatment (N = 14) reported that chemotherapy was significantly associated with cognitive decline with a dose-response relationship observed at 12 months (surveillance group: 0%; 2–3 cycles of chemotherapy: 52%; and 4–7 cycles of chemotherapy: 67%). Although the extent to which cisplatin-based chemotherapy may have negative effects on long-term cognitive function in TCS is unclear, cognitive complaints among long-term survivors are common and independent of treatment modality [88, 148–151]. These subjective complaints may reflect the effects of anxiety and depression, which are prevalent in TCS [148]. The first step in managing cognitive complaints may include managing specific stressors by implementing effective coping strategies.

12. Anxiety/Depression

A Norwegian study [153] reported a significantly higher prevalence of a Hospital Anxiety and Depression Scale (HADS-) defined anxiety disorder among TCS (mean follow-up time: 11.3 years) compared to age-adjusted men from the general population (19.2% versus 13.5%, P < 0.001). Young age, peripheral neuropathy, economic difficulties, excess alcohol use, sexual concerns, and prior treatment for mental illness were significantly associated with HADS-defined anxiety disorder [153]. A recent investigation [154] showed that the prevalence of clinically significant anxiety among TCS (mean: 11.6 years after diagnosis) in Germany was 61.6%. Anxiety was significantly associated with younger age at diagnosis and shorter time since diagnosis in multivariate analyses. Prior studies [153–156] reported that the prevalence of depression among TCS ranges from 7.9% to 20%, but the extent to which TCS may experience significantly more depressive orders compared to the general population is uncertain. Feeling helpless/hopeless [156], lower social support [156], a higher number of physical symptoms [154], and having children [154] were reported to be significantly associated with higher levels of depression.

13. Fatigue

Chronic fatigue, defined as symptoms with a duration of ≥6 months, is a common and distressing cancer-related adverse effect [157]. The prevalence of chronic cancer-related fatigue among Norwegian TCS was significantly higher compared to age-matched men in the general population (17.1% versus 9.7%) [158]. A recent longitudinal investigation [159] of 812 TCS treated between 1980 and 1994 in Norway reported that the prevalence of chronic fatigue increased from 15% at survey I (1998–2002) to 27% at survey II (2007-2008) (P < 0.001). Several factors were significantly associated with chronic fatigue in this study: [159] high level of neuropathy, Raynaud-like phenomena, testosterone level in the lowest quartile, low level of physical activity, as well as higher levels of anxiety and depression. Health care professionals should consider exercise and psychological interventions for early prevention and treatment of chronic fatigue among TCS. A recent meta-analysis of cancer survivors [160] reported that exercise and psychological interventions are effective for reducing cancer-related fatigue during and after cancer treatment and significantly more effective than available pharmaceutical options.

14. Adverse Health Outcomes

To develop risk-stratified, evidence-based follow-up recommendations for TCS, characterization of long-term adverse health outcomes (AHOs) is critical. A recent multi-institutional investigation [40] of 952 North American TCS examined the type and prevalence of AHOs after chemotherapy with four cycles of EP (EPX4) or three or four cycles of BEP (BEPX3/BEPX4) (Table 3). At a median age of 37 years, more than one-third of survivors reported three or more AHOs with similar prevalence and type after EPX4 and BEPX3, except for Raynaud phenomenon (11.6% versus 21.4%; P < 0.01), peripheral neuropathy (29.2% versus 21.4%; P = 0.02), and obesity (25.5% versus 33.0%; P = 0.04). The type and prevalence of AHOs after BEPX4 were largely similar to EPX4 and BEPX3. Increasing age at clinical evaluation, current tobacco use, and nonmarried status were associated with increased numbers of AHOs, whereas weekly vigorous decreased hip motion and/or limp, prompt evaluation with plain radiograph or MRI is critical [7].
| Adverse health outcomes (AHOs) | Total patients \((N=952)\) \(N(\%)\) | EP (4 cycles) \((N=294)\) \(N(\%)\) | BEP (3 cycles) \((N=364)\) \(N(\%)\) | BEP (4 cycles) \((N=170)\) \(N(\%)\) |
|-------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
| **Total number of AHOs**     |                                 |                                 |                                 |                                 |
| Median (range)               | 2 (0–11)                       | 2 (0–9)                         | 2 (0–11)                       | 2 (0–10)                       |
| 0                             | 194 (20.4)                     | 64 (21.8)                       | 83 (22.8)                      | 25 (14.7)                      |
| 1                             | 209 (21.9)                     | 68 (23.1)                       | 71 (19.5)                      | 42 (24.7)                      |
| 2                             | 191 (20.1)                     | 61 (20.8)                       | 82 (22.5)                      | 27 (15.9)                      |
| 3                             | 143 (15.0)                     | 48 (16.3)                       | 48 (13.2)                      | 25 (14.7)                      |
| 4                             | 96 (10.1)                      | 28 (9.5)                        | 38 (10.4)                      | 18 (10.6)                      |
| 5 or more                     | 119 (12.5)                     | 25 (8.5)                        | 42 (11.5)                      | 33 (19.4)                      |
| **Type of AHOs**†             |                                 |                                 |                                 |                                 |
| Yes                           | 353 (37.1)                     | 104 (35.4)                      | 130 (35.7)                     | 65 (38.2)                      |
| No†                          | 599 (62.9)                     | 190 (64.6)                      | 234 (64.3)                     | 105 (61.8)                     |
| **Hearing impairment**§       |                                 |                                 |                                 |                                 |
| Yes                           | 300 (31.5)                     | 95 (32.3)                       | 109 (30.0)                     | 56 (33.0)                      |
| No§                          | 652 (68.5)                     | 199 (67.7)                      | 255 (70.0)                     | 114 (67.0)                     |
| **Peripheral neuropathyǁ**    |                                 |                                 |                                 |                                 |
| Yes                           | 257 (27.0)                     | 86 (29.2)                       | 78 (21.4)                      | 54 (31.8)                      |
| Noǁ                          | 695 (73.0)                     | 208 (70.8)                      | 286 (78.6)                     | 116 (68.2)                     |
| **Peripheral neuropathy plus tinnitus and/or hearing issue** |                                 |                                 |                                 |                                 |
| Yes                           | 156 (16.4)                     | 49 (16.7)                       | 48 (13.2)                      | 31 (18.2)                      |
| No                            | 796 (83.6)                     | 245 (83.3)                      | 316 (86.8)                     | 139 (81.8)                     |
| **Hypertension and on prescription medication** |                                 |                                 |                                 |                                 |
| Yes                           | 110 (11.6)                     | 35 (11.9)                       | 45 (12.4)                      | 15 (8.8)                       |
| No‖                           | 842 (88.4)                     | 259 (88.1)                      | 319 (87.6)                     | 155 (91.2)                     |
| **Hypercholesterolemia and on prescription medication** |                                 |                                 |                                 |                                 |
| Yes                           | 100 (10.5)                     | 32 (10.9)                       | 31 (8.5)                       | 20 (11.8)                      |
| No‖                           | 852 (89.5)                     | 262 (89.1)                      | 333 (91.5)                     | 150 (88.2)                     |
| **Cardiovascular disease††** |                                 |                                 |                                 |                                 |
| Yes                           | 14 (1.5)                       | 4 (1.4)                         | 4 (1.1)                        | 2 (1.2)                        |
| No††                          | 938 (98.5)                     | 290 (98.6)                      | 360 (98.9)                     | 168 (98.8)                     |
| **Raynaud phenomenon**        |                                 |                                 |                                 |                                 |
| Yes                           | 178 (18.7)                     | 34 (11.6)                       | 78 (21.4)                      | 49 (28.8)                      |
| No§§                          | 774 (81.3)                     | 260 (88.4)                      | 286 (78.6)                     | 121 (71.2)                     |
| **Peripheral vascular disease** |                                 |                                 |                                 |                                 |
| Yes                           | 29 (3.0)                       | 5 (1.7)                         | 8 (2.2)                        | 10 (5.9)                       |
| No§§                          | 923 (97.0)                     | 289 (98.3)                      | 356 (97.8)                     | 160 (94.1)                     |
| **Thromboembolic disease¶¶** |                                 |                                 |                                 |                                 |
| Yes                           | 5 (0.5)                        | 0                               | 0                               | 4 (2.4)                        |
| No                            | 947 (99.5)                     | 294 (100)                       | 364 (100)                      | 166 (97.6)                     |
| **Renal disease**             |                                 |                                 |                                 |                                 |
| Yes                           | 25 (2.6)                       | 7 (2.4)                         | 6 (1.6)                        | 7 (4.1)                        |
| No¶¶                          | 927 (97.4)                     | 287 (97.6)                      | 358 (98.4)                     | 163 (95.9)                     |
| **Diabetes and on prescription medication†††** |                                 |                                 |                                 |                                 |
| Yes                           | 30 (3.1)                       | 9 (3.1)                         | 10 (2.7)                       | 3 (1.8)                        |
| No†††                          | 922 (96.9)                     | 285 (96.9)                      | 354 (97.3)                     | 167 (98.2)                     |
| **Benign thyroid disease**    |                                 |                                 |                                 |                                 |
| Yes                           | 23 (2.4)                       | 6 (2.0)                         | 9 (2.5)                        | 5 (2.9)                        |
Table 3: Continued.

| Adverse health outcomes (AHOs) | Total patients (N = 952) N (%) | EP (4 cycles) (N = 294) N (%) | Treatment regimen |
|--------------------------------|--------------------------------|-------------------------------|-------------------|
| No***                          | 929 (97.6)                    | 288 (98.0)                    | 355 (97.5)        | 165 (97.1) |
| **Problems with balance/vertigo/dizziness** | 89 (9.3) | 26 (8.8) | 37 (10.2) | 16 (9.4) |
| No                             | 863 (90.7)                    | 268 (91.2)                    | 327 (89.8)        | 154 (90.6) |
| **Hypogonadism with testosterone therapy** | 93 (9.9) | 25 (8.6) | 37 (10.3) | 16 (9.5) |
| No                             | 851 (90.1)                    | 267 (91.4)                    | 323 (89.7)        | 152 (90.5) |
| **Erectile dysfunction**       | 115 (12.1)                    | 28 (9.5)                      | 39 (10.7)         | 34 (20.0) |
| No**                           | 837 (87.9)                    | 266 (90.5)                    | 325 (89.3)        | 136 (80.0) |
| **Psychotropic prescription medication for anxiety and/or depression** | 99 (10.4) | 34 (11.6) | 27 (7.4) | 20 (11.8) |
| No                             | 853 (89.6)                    | 260 (88.4)                    | 337 (92.6)        | 150 (88.2) |

*Adapted with permission from Fung et al. [40] (Table 3). BEP: bleomycin, etoposide, cisplatin; CAD: coronary artery disease; EP: etoposide, cisplatin; MI: myocardial infarction. P values are derived from the chi-square test comparing the proportions of AHOs reported by TCS in the EPX4 and BEPX3 treatment groups. Except for Raynaud phenomenon (P < 0.01) and peripheral neuropathy (P = 0.02), the P values for all other AHOs were >0.05; category includes 3 participants for whom this outcome was not stated; among all 952 participants, 270 (28.4%) reported problems hearing words, sounds, or language in crowds, 13 (1.4%) required hearing aid, and 2 (0.2%) had complete deafness (questions derived from the hearing handicap inventory by Ventry and Weinstein) [166]; 109 (11.4%) had “quite a bit” or “very much” difficulty hearing and 75 (7.9%) had “quite a bit” or “very much” reduced hearing (EORTC-CIPN20 and SCIN) ([167, 168]). Category includes 48 participants for whom this outcome was not stated; among all 952 participants, the number of patients reporting “quite a bit” or “very much” to the following questions are as follows: 123 (12.9%) tingling fingers or hands, 167 (17.5%) tingling toes or feet, 121 (12.7%) numbness in fingers or hands, 161 (16.9%) numbness in toes or feet, 34 (3.6%) shooting/burning pain in fingers or hands, 70 (7.4%) shooting/burning pain in toes or feet (EORTC-CIPN20) [167]; 134 (14.1%) pain and tingling in toes or feet, and 86 (9.0%) pain and tingling in hands or fingers (SCIN) [168]. Category includes 16 participants for whom this outcome was not stated; category includes 11 participants for whom this outcome was not stated; ** category includes 3 participants for whom this outcome was not stated; *** includes coronary artery disease, heart failure, and cerebrovascular disease (categories not mutually exclusive, and each category was counted as one AHO). Among all participants, 7 (0.7%) reported coronary artery disease (3 occurrences for coronary artery disease, 5 occurrences of angioplasty or stent, and 5 occurrences of heart attack or myocardial infarction); 1 patient reported heart failure; and 10 (1.0%) reported cerebrovascular disease (6 occurrences of transient ischemic attacks, 4 occurrences of stroke, and 1 occurrence of carotid artery surgery); ** category includes 21 participants for whom this outcome was not stated; *** category includes 12 participants for whom this outcome was not stated; **** category includes 19 participants for whom this outcome was not stated; ***** category includes 26 participants for whom this outcome was not stated; ****** category includes 3 participants for whom this outcome was not stated; ******* category includes 12 participants for whom this outcome was not stated; ^** of the 89 patients, 47 reported persistent dizziness or vertigo and 63 reported symptoms of dizziness when standing up (categories not mutually exclusive). Category includes 40 participants for whom this outcome was not stated; ** eight participants who underwent bilateral orchiectomy were excluded from this category; *** category include 7 participants for whom this outcome was not stated; **** participants could report more than one psychotropic medication. Psychotropic medications used by the 99 participants include aripiprazole (n = 2), alprazolam (n = 5), amphetamine-dextroamphetamine (n = 9), bupropion (n = 10), buspirone (n = 1), cilomilast (n = 6), clonazepam (n = 8), desvenlafaxine (n = 1), diazepam (n = 1), duloxetine (n = 7), escitalopram (n = 16), fluvoxamine (n = 1), fluoxetine (n = 4), hydroxyzine (n = 1), lisdexamfetamine (n = 4), lorazepam (n = 6), methylphenidate (n = 5), nortriptyline (n = 2), paroxetine (n = 7), trazodone (n = 5), sertraline (n = 11), and venlafaxine (n = 7).

physical activity was protective (P < 0.05). Self-reported health was excellent/very good in approximately 60% of TCS, but this proportion decreased as number of AHOs increased (P < 0.001) (Figure 2).

15. Conclusions

Due to their young age at diagnosis, long-term survival, and current use of largely homogeneous therapies, TCS comprise an ideal cohort for adult-onset cancer survivorship research [161]. Moreover, these patients now comprise approximately 4% of all male cancer survivors [162]. Table 4 summarizes major research priorities for TC survivors set forth at an international consensus conference [161]. An overarching recommendation was the development of longitudinal cohort studies to evaluate the life-long burden and latency trends of medical and psychosocial morbidities by category of treatment. TC is relatively unique among cancer types in that it provides for the ready availability of a “comparison group” cured with surgery only without the confounding effects of cytotoxic treatment, with which to compare the late effects of radiotherapy and chemotherapy. Moreover, study of the surgery-only group itself is informative and presents a unique opportunity to study the long-term history of a cancer cured without cytotoxic therapy, including any inherently preprogrammed development of adverse metabolic and other outcomes. This type of proposed cohort investigation, which gathers comprehensive exposure and outcome...
Figure 2: Proportion of testicular cancer survivors (TCS) with excellent, very good, good, fair, and poor self-reported health by number of adverse health outcomes (AHOs). P value for association of number of AHOs with self-reported health was <0.01 (Mantel 1 df chi-square test of trend). Self-reported health was not indicated by one participant with 1-2 AHOs and one participant with 3-4 AHOs. * Adapted with permission from Fung et al. [40] (Figure 1).

Table 4: Summary of major research recommendations: late effects of testicular cancer and its treatment.

(1) **Overarching recommendation: lifelong follow-up of all testicular cancer survivors (TCS)**
   (i) Integrate observational and analytic epidemiologic studies with molecular and genetic approaches to ascertain the risk of emerging toxicities and to understand the evolution of known late effects, especially with the aging of TCS.
   (ii) Evaluate the influence of race and socioeconomic status (SES) on the late effects of TC and its treatment.
   (iii) Characterize long-term tissue deposition of platinum (sites and reactivity), serum levels, and correlation with late effects.
   (iv) Evaluate the life-long burden of medical and psychosocial morbidity by treatment.
   (v) Utilize research findings to establish evidence-based, risk-adapted, long-term follow-up care.

(2) **Specific recommendations**
   (i) Second malignant neoplasms (SMN) and late relapses
      (a) Determine the effect of reductions in field size and dose of radiotherapy, along with the use of carboplatin as adjuvant therapy in seminoma patients, on the risk of SMN.
      (b) Examine relation between platinum-based chemotherapy and site-specific risk of solid tumors, the associated temporal patterns, and the influence of age at exposure and attained age.
      (c) Compare risk of SMN in TCS managed with surgery alone to cancer incidence in the general male population.
      (d) Examine delaying influence of platinum-based chemotherapy (and duration and magnitude of effect) on development of contralateral testicular cancer.
      (e) Characterize the evolution of cured testicular cancer, in particular, the molecular underpinnings of late recurrences.
   (ii) Cardiovascular disease (CVD)
      (a) Evaluate the contributions and interactions of subclinical hypogonadism, platinum-based chemotherapy, radiotherapy, lifestyle factors (diet, tobacco use, and physical activity), body mass index, family history of CVD, race, socioeconomic status, abnormal laboratory values, and genetic modifiers.
      (b) Develop comprehensive risk prediction models, considering the above variables, to stratify TCS into risk groups in order to customize follow-up strategies and develop evidence-based interventions.
   (iii) Neurotoxicity
      (a) Evaluate evolution of neurotoxicity across TCS lifespan, role of genetic modifiers, and extent to which symptoms impact on work ability and quality of life.
   (iv) Nephrotoxicity
      (a) Determine whether the natural decline in renal function associated with aging is accelerated in TCS, any influence of low-level platinum exposure, and the impact of decreased GFR on CVD and all-cause mortality.
      (b) Determine the incidence of hypomagnesemia, together with the role of modifying factors and resultant medical consequences, in long-term TCS.
data, can provide the basis for identifying predictors of AHOs, either singly or jointly, for the eventual development of preventive and interventional measures. An important goal not only for TCS, but for cancer survivors in general, is the identification of genetic variants that predispose to the development of acute and long-term treatment toxicities. This elucidation of etiopathogenetic pathways provides another step towards developing targeted prevention and intervention strategies to optimize risk-based care, minimize chronic morbidities, and improve patients’ quality of life.

**Conflicts of Interest**

The authors declare that there are no conflicts of interest regarding the publication of this paper.

**References**

[1] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer Statistics, 2017,” *CA: A Cancer Journal for Clinicians*, vol. 67, no. 1, pp. 7–30, 2017.

[2] L. H. Einhorn and J. Donohue, “Cis-diaminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer,” *Annals of Internal Medicine*, vol. 87, no. 3, pp. 293–298, 1977.

[3] N. Hanna and L. H. Einhorn, “Testicular cancer: a reflection on 50 years of discovery,” *Journal of Clinical Oncology*, vol. 32, no. 28, pp. 3085–3092, 2014.

[4] A. Verdeccia, S. Francisci, H. Brenner et al., “Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data,” *Lancet Oncology*, vol. 8, no. 9, pp. 784–796, 2007.

[5] L. H. Einhorn, “Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture,” *Cancer Research*, vol. 41, no. 1, pp. 3275–3280, 1981.

[6] L. B. Travis, A. K. Ng, J. M. Allan et al., “Second malignant neoplasms and cardiovascular disease following radiotherapy,” *Journal of the National Cancer Institute*, vol. 104, no. 5, pp. 357–370, 2012.

[7] H. S. Haugnes, G. J. Bosl, H. Boer et al., “Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up,” *Journal of Clinical Oncology*, vol. 30, no. 30, pp. 3752–3763, 2012.

[8] N. M. Aziz, “Cancer survivorship research: state of knowledge, challenges and opportunities,” *Acta Oncologica*, vol. 46, no. 4, pp. 417–432, 2007.

[9] D. R. Feldman, W. L. Schaffer, and R. M. Steingart, “Late cardiovascular toxicity following chemotherapy for germ cell tumors,” *Journal of the National Comprehensive Cancer Network*, vol. 10, no. 4, pp. 537–544, 2012.

---

**Table 4: Continued.**

(v) Hypogonadism and decreased fertility
(a) Address the incidence, course, and clinical effects of subclinical hypogonadism.
(b) Evaluate effect of all levels of gonadal dysfunction in TCS on CVD, premature aging, fatigue, osteoporosis, mental health, quality of life, and sexuality.

(vi) Pulmonary function
(a) Examine role of platinum compounds on long-term pulmonary damage in TCS, and interactions with other influences, including bleomycin, tobacco use, and occupational risk factors.

(vii) Psychosocial effects
(a) Identify prevalence and predictors of depression, cancer-related anxiety, fatigue, infertility-related distress, problems with sexuality and paired relationships, and posttraumatic growth.
(b) Examine the impact of different cultural backgrounds on posttreatment quality of life.
(c) Evaluate TCS work ability throughout life.
(d) Determine whether normal age-related declines in cognitive function are accelerated in TCS.

(3) **Interventions**
(i) Conduct targeted intervention trials aimed at promoting smoking cessation, healthy dietary habits, and an increase in physical activity.
(ii) Evaluate the role of information and communication technologies in promoting a healthy lifestyle among TCS.
(iii) Consider randomized, pharmacologic intervention trials among TCS with biochemical parameters approaching threshold values to avoid accelerated development into treatment-requiring CVD.
(iv) Determine optimal schedule of testosterone replacement therapy among TCS with clinical hypogonadism.

(4) **Genetic and molecular considerations**
(i) Evaluate genetic risk factors (identified in the general male population) as modifiers for all late effects in TCS, in particular, CVD, SMN, neurotoxicity, nephrotoxicity, hypogonadism, and psychosocial effects.
(ii) Investigate the role of genome-wide association studies, epigenetics, mitochondrial DNA, microRNA, proteomics and related approaches in identifying genetic variants that contribute to the late effects of treatment.
(iii) Develop standardized procedures for biospecimen collection to support genetic and molecular studies, as reviewed previously.

(5) **Risk prediction models**
(i) Develop comprehensive risk prediction models that incorporate genetic modifiers of late sequelae.

*Adapted with permission from Travis et al. [161] (Table 2).
[10] J. F. Christensen, M. Bandak, A. Campbell, L. W. Jones, and P. Hjøsmann, "Treatment-related cardiovascular late effects and exercise training countermeasures in testicular germ cell cancer survivorship," *Acta Oncologica*, vol. 54, no. 5, pp. 592–599, 2015.

[11] L. Y. Dirix, M. Libura, J. Libura, P. B. Vermeulen, E. A. De Brujin, and A. T. Van Oosterom, "In vitro toxicity studies with mitomycins and bleomycin on endothelial cells," *Anticancer Drugs*, vol. 8, no. 9, pp. 859–868, 1997.

[12] Y. Shi, S. Inoue, R. Shinozaki, K. Fukue, and T. Kugo, "Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro," *Japanese Journal of Cancer Research*, vol. 89, no. 7, pp. 757–767, 1998.

[13] K. P. Dieckmann, W. J. Struss, and U. Budde, "Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour," *Anticancer Research*, vol. 31, no. 12, pp. 4501–4505, 2011.

[14] J. Nuver, A. J. Smit, D. T. Sleijfer et al., "Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer," *European Journal of Cancer*, vol. 40, no. 5, pp. 701–706, 2004.

[15] J. Nuver, A. J. Smit, J. van der Meer et al., "Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer," *Journal of Clinical Oncology*, vol. 23, no. 36, pp. 9130–9137, 2005.

[16] M. T. Meinardi, J. A. Gietema, W. T. van der Graaf et al., "Cardiovascular morbidity in long-term survivors of metastatic testicular cancer," *Journal of Clinical Oncology*, vol. 18, no. 8, pp. 1725–1732, 2000.

[17] H. C. Gerstein, J. F. Mann, Q. Yi et al., "Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals," *Journal of the American Medical Association*, vol. 286, no. 4, pp. 421–426, 2001.

[18] D. H. O'Leary, J. F. Polak, R. A. Kronmal et al., "Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group," *New England Journal of Medicine*, vol. 340, no. 1, pp. 14–22, 1999.

[19] L. D. van Schinkel, P. M. Willems, R. W. van der Meer et al., "Chemotherapy for testicular cancer induces acute alterations in diastolic heart function," *British Journal of Cancer*, vol. 109, no. 4, pp. 891–896, 2013.

[20] D. J. Brenner and E. J. Hall, "Computed tomography—an increasing source of radiation exposure," *New England Journal of Medicine*, vol. 357, no. 22, pp. 2277–2284, 2007.

[21] R. L. Schilske and T. Anderson, "Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin," *Annals of Internal Medicine*, vol. 90, no. 6, pp. 929–931, 1979.

[22] P. D. Turlapaty and B. M. Altura, "Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease," *Science*, vol. 208, no. 4440, pp. 198–200, 1980.

[23] N. J. Vogelzang, J. L. Torkelson, and B. J. Kennedy, "Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin," *Cancer*, vol. 56, no. 12, pp. 2765–2770, 1985.

[24] G. I. Togna, A. R. Togna, M. Franconi, and L. Caprino, "Cisplatin triggers platelet activation," *Thrombosis Research*, vol. 99, no. 5, pp. 503–509, 2000.

[25] D. Lechner, M. Kollars, A. Gleiss, P. A. Kyrie, and A. Weltermann, "Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity," *Journal of Thrombosis and Haemostasis*, vol. 5, no. 12, pp. 2445–2452, 2007.

[26] D. Bissett, L. Kunkeler, L. Zwanenburg et al., "Long-term sequelae of treatment for testicular germ cell tumours," *British Journal of Cancer*, vol. 62, no. 4, pp. 655–659, 1990.

[27] C. Bokemeyer and H. J. Schmoll, "Secondary neoplasms following treatment of malignant germ cell tumors," *Journal of Clinical Oncology*, vol. 11, no. 9, pp. 1703–1709, 1993.

[28] M. Brydoy, J. Oldenburg, O. Klepp et al., "Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors," *Journal of the National Cancer Institute*, vol. 101, no. 24, pp. 1682–1695, 2009.

[29] J. L. Glendenning, Y. Barbachano, A. R. Norman et al., "Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer," *Cancer*, vol. 116, no. 10, pp. 2322–2331, 2010.

[30] D. Strumberg, S. Brugge, M. W. Korn et al., "Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-semimomatous testicular cancer," *Annals of Oncology*, vol. 13, no. 2, pp. 229–236, 2002.

[31] R. de Wit, G. Stoter, S. B. Kaye et al., "Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group," *Journal of Clinical Oncology*, vol. 15, no. 5, pp. 1837–1843, 1997.

[32] C. Bokemeyer, C. C. Berger, M. A. Kuczyk, and H. J. Schmoll, "Evaluation of long-term toxicity after chemotherapy for testicular cancer," *Journal of Clinical Oncology*, vol. 14, no. 11, pp. 2923–2932, 1996.

[33] H. S. Haugnes, N. Aass, S. D. Fossa et al., "Components of the metabolic syndrome in long-term survivors of testicular cancer," *Annals of Oncology*, vol. 18, no. 2, pp. 241–248, 2007.

[34] H. S. Haugnes, T. Wethal, N. Aass et al., "Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study," *Journal of Clinical Oncology*, vol. 28, no. 30, pp. 4649–4657, 2010.

[35] R. A. Huddart, A. Norman, M. Shahidi et al., "Cardiovascular disease as a long-term complication of treatment for testicular cancer," *Journal of Clinical Oncology*, vol. 21, no. 8, pp. 1513–1523, 2003.

[36] J. Nuver, A. J. Smit, B. H. Wolffenbuttel et al., "The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer," *Journal of Clinical Oncology*, vol. 23, no. 22, pp. 4980–4990, 2005.

[37] P. M. Willems, J. Burggraaf, N. A. Hamdy et al., "Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors," *British Journal of Cancer*, vol. 109, no. 1, pp. 60–67, 2013.

[38] E. C. de Haas, R. Altena, H. M. Boezen et al., "Early death and neurological side effects in testicular cancer survivorship," *British Journal of Cancer*, vol. 56, no. 4, pp. 585–590, 1987.

[39] C. Bokemeyer and H. J. Schmoll, "Secondary neoplasms following treatment of malignant germ cell tumors," *Journal of Clinical Oncology*, vol. 11, no. 9, pp. 1703–1709, 1993.

[40] P. M. Willems, J. Burggraaf, N. A. Hamdy et al., "Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors," *British Journal of Cancer*, vol. 109, no. 1, pp. 60–67, 2013.

[41] E. C. de Haas, R. Altena, H. M. Boezen et al., "Early development of the metabolic syndrome after chemotherapy for testicular cancer," *Annals of Oncology*, vol. 24, no. 3, pp. 749–755, 2013.

[42] C. Fung, H. D. Sesso, A. M. Williams et al., "Multi-institutional assessment of adverse health outcomes among north American testicular cancer survivors after modern cisplatin-based chemotherapy," *Journal of Clinical Oncology*, vol. 35, no. 11, pp. 1211–1222, 2017.
[41] C. Bogefors, S. Isaksson, J. Bobjer et al., "Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome," Andrology, vol. 5, no. 4, pp. 711–717, 2017.

[42] A. M. Traish, F. Saad, R. J. Feeley, and A. Guay, "The dark side of testosterone deficiency: I. Type 2 diabetes and insulin resistance," Journal of Andrology, vol. 30, no. 5, pp. 477–494, 2009.

[43] A. M. Traish, F. Saad, and A. Guay, "The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance," Journal of Andrology, vol. 30, no. 5, pp. 23–32, 2009.

[44] A. M. Traish, A. Guay, R. Feeley, and F. Saad, "The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction," Journal of Andrology, vol. 30, no. 5, pp. 10–22, 2009.

[45] L. W. Jones, M. J. Haykowsky, J. J. Swartz, P. S. Douglas, and J. R. Mackey, "Early breast cancer therapy and cardiovascular injury," Journal of the American College of Cardiology, vol. 50, no. 15, pp. 1435–1441, 2007.

[46] A. W. van den Belt-Dusebout, R. de Wit, J. A. Gietema et al., "Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer," Journal of Clinical Oncology, vol. 25, no. 28, pp. 4370–4378, 2007.

[47] A. W. van den Belt-Dusebout, J. Nuver, R. de Wit et al., "Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer," Journal of Clinical Oncology, vol. 24, no. 3, pp. 467–475, 2006.

[48] S. D. Fossa, E. Gilbert, G. M. Dores et al., "Noncancer causes of death in survivors of testicular cancer," Journal of the National Cancer Institute, vol. 99, no. 7, pp. 533–544, 2007.

[49] S. R. Alanee, D. R. Feldman, P. Russo et al., "Long-term mortality in patients with germ cell tumors: effect of primary cancer site on cause of death," Urologic Oncology, vol. 32, no. 1, pp. 26.e9–26.e15, 2014.

[50] C. Fung, S. D. Fossa, M. T. Milano et al., "Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population-based study," Journal of Clinical Oncology, vol. 33, no. 28, pp. 3105–3115, 2015.

[51] A. S. Go, D. Mozaffarian, V. L. Roger et al., "Heart disease and stroke statistics–2014 update: a report from the American Heart Association," Circulation, vol. 129, no. 3, pp. e28–e292, 2014.

[52] D. C. Goff Jr., D. M. Lloyd-Jones, G. Bennett et al., "2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines," Circulation, vol. 129, no. 2, pp. S49–S73, 2013.

[53] M. E. Wood, V. Vogel, A. Ng, L. Foxhall, P. Goodwin, and L. B. Travis, "Second malignant neoplasms: assessment and strategies for risk reduction," Journal of Clinical Oncology, vol. 30, no. 30, pp. 3734–3745, 2012.

[54] L. B. Travis, C. S. Rabkin, L. M. Brown et al., "Cancer survivorship–genetic susceptibility and second primary cancers: research strategies and recommendations," Journal of the National Cancer Institute, vol. 98, no. 1, pp. 15–25, 2006.

[55] L. B. Travis, S. D. Fossa, S. J. Schonfeld et al., "Second cancers among 40,576 testicular cancer patients: focus on long-term survivors," Journal of the National Cancer Institute, vol. 97, no. 18, pp. 1354–1365, 2005.

[56] L. B. Travis, M. Andersson, M. Gospodarowicz et al., "Treatment-associated leukemia following testicular cancer," Journal of the National Cancer Institute, vol. 92, no. 14, pp. 1165–1171, 2000.

[57] L. B. Travis, R. E. Curtis, H. Storm et al., "Risk of second malignant neoplasms among long-term survivors of testicular cancer," Journal of the National Cancer Institute, vol. 89, no. 19, pp. 1429–1439, 1997.

[58] M. Hauptmann, S. D. Fossa, M. Stovall et al., "Increased stomach cancer risk following radiotherapy for testicular cancer," British Journal of Cancer, vol. 112, no. 1, pp. 44–51, 2015.

[59] M. Hauptmann, T. Borge Johannesen, E. S. Gilbert et al., "Increased pancreatic cancer risk following radiotherapy for testicular cancer," British Journal of Cancer, vol. 115, no. 7, pp. 901–908, 2016.

[60] A. W. van den Belt-Dusebout, B. M. Aleman, G. Besseling et al., "Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy," International Journal of Radiation Oncology, Biology, Physics, vol. 75, no. 5, pp. 1420–1429, 2009.

[61] J. M. Bachaud, F. Berthier, M. Soulie et al., "Second non-germ cell malignancies in patients treated for stage I-II testicular seminoma," Radiotherapy and Oncology, vol. 50, no. 2, pp. 191–197, 1999.

[62] N. H. Hanna and L. H. Einhorn, "Testicular cancer–discoveries and updates," New England Journal of Medicine, vol. 371, no. 21, pp. 2005–2016, 2014.

[63] D. F. Bajorin, M. F. Sarosdy, D. G. Pfister et al., "Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study," Journal of Clinical Oncology, vol. 11, no. 4, pp. 598–606, 1993.

[64] C. Kollmannsberger, J. Beyer, J. P. Droz et al., "Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors," Journal of Clinical Oncology, vol. 16, no. 10, pp. 3386–3391, 1998.

[65] C. Kollmannsberger, J. T. Hartmann, L. Kanz et al., "Therapy-related malignancies following treatment of germ cell cancer," International Journal of Cancer, vol. 83, no. 6, pp. 860–863, 1999.

[66] E. H. Wanders, S. D. Fossa, and S. Tretli, "Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients," European Journal of Cancer, vol. 33, no. 2, pp. 253–262, 1997.

[67] C. Fung, S. D. Fossa, M. T. Milano, J. Oldenburg, and L. B. Travis, "Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study," Journal of Clinical Oncology, vol. 31, no. 10, pp. 3807–3814, 2013.

[68] S. D. Fossa, J. Chen, S. J. Schonfeld et al., "Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men," Journal of the National Cancer Institute, vol. 97, no. 14, pp. 1056–1066, 2005.

[69] P. B. Rossen, A. F. Pedersen, R. Zachariae, and H. von der Maase, "Health-related quality of life in long-term survivors of testicular cancer," Journal of Clinical Oncology, vol. 27, no. 35, pp. 5993–5999, 2009.

[70] S. D. Williams, R. Birch, L. H. Einhorn, L. Irwin, F. A. Greco, and P. J. Loehrer, "Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide," New England Journal of Medicine, vol. 316, no. 23, pp. 1435–1440, 1987.

[71] M. Sprauten, T. H. Darrah, D. R. Peterson et al., "Impact of long-term serum platinum concentrations on neuro- and otoxicity in Cisplatin-treated survivors of testicular cancer," Journal of Clinical Oncology, vol. 30, no. 3, pp. 300–307, 2012.
[72] J. Oldenburg, S. M. Kraggerud, M. Brydoy, M. Cvancarova, R. A. Lothe, and S. D. Fossa, “Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study,” Journal of Translational Medicine, vol. 5, no. 1, p. 70, 2007.

[73] M. E. Dolan, O. El Charif, H. E. Wheeler, E. R. Gamazon et al., “Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer,” Clinical Cancer Research, vol. 23, no. 19, pp. 5757–5768, 2017.

[74] A. Sawant, A. Kothandapani, A. Zhitkovich, R. W. Sobol, and S. M. Patrick, “Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links,” DNA Repair, vol. 35, pp. 126–136, 2015.

[75] J. C. Morales, P. Richard, A. Rommel et al., “Kub5-Hera, the human Rtt103 homolog, plays dual functional roles in transcription termination and DNA repair,” Nucleic Acids Research, vol. 42, no. 8, pp. 4996–5006, 2014.

[76] D. L. Hershman, C. Lacchetti, R. H. Dworkin et al., “Prevention of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline,” Journal of Clinical Oncology, vol. 32, no. 18, pp. 1941-1967, 2014.

[77] C. A. Bauer and T. J. Brozoski, “Cochlear structure and function after round window application of ototoxins,” Hearing Research, vol. 201, no. 1-2, pp. 121-131, 2003.

[78] C. Bokemeyer, C. C. Berger, J. T. Hartmann et al., “Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer,” British Journal of Cancer, vol. 77, no. 8, pp. 1355–1362, 1998.

[79] R. D. Frisina, H. E. Wheeler, S. D. Fossa et al., “Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer,” Journal of Clinical Oncology, vol. 34, no. 23, pp. 2712–2720, 2016.

[80] L. P. Rybak, “Mechanisms of cisplatin ototoxicity and progress in otoprotection,” Current Opinion in Otalaryngology & Head and Neck Surgery, vol. 15, no. 5, pp. 364–369, 2007.

[81] L. Riedemann, C. Lanvers, D. Deuster et al., “Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin,” Pharmacogenomics Journal, vol. 8, no. 1, pp. 23–28, 2008.

[82] J. Oldenburg, S. M. Kraggerud, M. Cvancarova, R. A. Lothe, and S. D. Fossa, “Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors,” Journal of Clinical Oncology, vol. 25, no. 6, pp. 708–714, 2007.

[83] C. J. Ross, H. Katzov-Eckert, M. P. Dube et al., “Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy,” Nature Genetics, vol. 41, no. 12, pp. 1345–1349, 2009.

[84] H. E. Wheeler, E. R. Gamazon, R. D. Frisina et al., “Variants in WFS1 and other Mendelian deafness genes are associated with cisplatin-associated ototoxicity,” Clinical Cancer Research, vol. 23, no. 13, pp. 3325–3333, 2016.

[85] H. E. Wheeler, R. D. Frisina, E. R. Gamazon et al., “Genome-wide association study (GWAS) of cisplatin-related hearing loss in testicular cancer survivors (TCS) to reveal associated variant in wolfram syndrome 1 (WFS1) gene,” Journal of Clinical Oncology, vol. 34, no. 15, p. 10015, 2016.

[86] K. Cryns, T. A. Sivakumaran, J. M. Van den Ouweland et al., “Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease,” Human Mutation, vol. 22, no. 4, pp. 273–287, 2003.

[87] H. Inoue, Y. Tanizawa, J. Wasson et al., “A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (wolfram syndrome),” Nature Genetics, vol. 20, no. 2, pp. 143–148, 1998.

[88] S. D. Fossa, R. de Wit, J. T. Roberts et al., “Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/ Medical Research Council Testicular Cancer Study Group (30941/TE20),” Journal of Clinical Oncology, vol. 21, no. 6, pp. 1107–1118, 2003.

[89] I. M. O’Sullivan, R. A. Huddart, A. R. Norman, J. Nicholls, D. P. Dearnaley, and A. Horwich, “Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours,” Annals of Oncology, vol. 14, no. 1, pp. 91–96, 2003.

[90] A. B. Simpson, J. Paul, J. Graham, and S. B. Kaye, “Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours,” British Journal of Cancer, vol. 78, no. 8, pp. 1061–1066, 1998.

[91] S. Sleijfer, “Bleomycin-induced pneumonitis,” Chest, vol. 120, no. 2, pp. 617–624, 2001.

[92] H. S. Haugnes, N. Aass, S. D. Fossa et al., “Pulmonary function in long-term survivors of testicular cancer,” Journal of Clinical Oncology, vol. 27, no. 17, pp. 2779–2786, 2009.

[93] H. S. Haugnes, J. Oldenburg, and R. M. Bremnes, “Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors,” Urologic Oncology, vol. 33, no. 9, pp. 399–406, 2015.

[94] S. M. Donat and D. A. Levy, “Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?,” Journal of Urology, vol. 160, no. 4, pp. 1347–1352, 1998.

[95] R. de Wit, S. Sleijfer, S. B. Kaye et al., “Bleomycin and scuba diving: where is the harm?,” Lancet Oncology, vol. 8, no. 11, pp. 954-955, 2007.

[96] A. A. Ferrando, A. M. Pendas, E. Llano, G. Velasco, R. Lidereau, and C. López-Otín, “Gene characterization, promoter analysis, and chromosomal localization of human bleomycin hydrolase,” Journal of Biological Chemistry, vol. 272, no. 52, pp. 33298–33304, 1997.

[97] J. Nuver, M. F. LutkeHolzik, M. van Zweeden et al., “Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients,” Pharmacogenetics and Genomics, vol. 15, no. 6, pp. 399–405, 2005.

[98] A. E. Vickers, K. Rose, R. Fisher, M. Saulnier, P. Sahota, and P. Bentley, “Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology,” Toxicologic Pathology, vol. 32, no. 5, pp. 577–590, 2004.

[99] H. Tanaka, E. Ishikawa, S. Teshima, and E. Shimizu, “Histopathological study of human cisplatin nephropathy,” Toxicologic Pathology, vol. 14, no. 1, pp. 247–257, 1986.

[100] S. D. Fossa, N. Aass, M. Winderen, O. P. Børner, and D. R. Olsen, “Long-term renal function after treatment for malignant germ-cell tumours,” Annals of Oncology, vol. 13, no. 2, pp. 222–228, 2002.

[101] S. W. Hansen, S. Groth, G. Daugaard, N. Rossing, and E. Shimizu, “Aspiration pneumonia in patients with testicular cancer,” Journal of Clinical Oncology, vol. 35, pp. 126–136, 2017.
undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer,” *Urology*, vol. 73, no. 2, pp. 328–331, 2009.

[134] C. L. Coogan, M. J. Hejase, G. R. Wahle et al., “Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer,” *Journal of Urology*, vol. 156, no. 5, pp. 1656–1658, 1996.

[135] A. Heidenreich, D. Pfüster, R. Witthuhn, D. Thüer, and P. Albers, “Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection,” *European Urology*, vol. 55, no. 1, pp. 217–224, 2009.

[136] A. W. Loren, P. B. Mangu, L. N. Beck et al., “Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update,” *Journal of Clinical Oncology*, vol. 31, no. 19, pp. 2500–2510, 2013.

[137] E. W. Winquist, G. S. Bauman, and J. Balogh, “Nontraumatic osteonecrosis after chemotherapy for testicular cancer: a systematic review,” *American Journal of Clinical Oncology*, vol. 24, no. 6, pp. 603–606, 2001.

[138] A. M. Cook, A. S. Dzik-Jurasz, A. R. Padhani, A. Norman, and R. A. Huddart, “The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours,” *British Journal of Cancer*, vol. 85, no. 11, pp. 1624–1626, 2001.

[142] M. B. de Ruiter, L. Reneman, W. Boogerd et al., “Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer,” *Human Brain Mapping*, vol. 32, no. 8, pp. 1206–1219, 2011.

[143] S. R. Kesler, F. C. Bennett, M. L. Mahaffey, and D. Spiegel, “Regional brain activation during verbal declarative memory in metastatic breast cancer,” *Clinical Cancer Research*, vol. 15, no. 21, pp. 6665–6673, 2009.

[144] D. H. Silverman, C. J. Dy, S. A. Castellon et al., “Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy,” *Breast Cancer Research and Treatment*, vol. 103, no. 3, pp. 303–311, 2007.

[145] B. Weiss, “Chemobrain: a translational challenge for neurotoxicology,” *Neurotoxicology*, vol. 29, no. 5, pp. 891–898, 2008.

[146] A. Amidi, L. M. Wu, M. Agerback et al., “Cognitive impairment and potential biological and psychological correlates of neuropsychological performance in recently orchietomized testicular cancer patients,” *Psycho-Oncology*, vol. 24, no. 9, pp. 1174–1180, 2015.

[147] J. S. Wefel, D. J. Vidrine, T. L. Veramonti et al., “Cognitive impairment in men with testicular cancer prior to adjuvant therapy,” *Cancer*, vol. 117, no. 1, pp. 190–196, 2011.

[148] S. B. Schagen, W. Boogerd, M. J. Muller et al., “Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer,” *Acta Oncologica*, vol. 47, no. 1, pp. 63–70, 2008.

[149] A. D. Pedersen, P. Rossen, M. Y. Mehlson et al., “Long-term cognitive function following chemotherapy in patients with testicular cancer,” *Journal of the International Neuropsychological Society*, vol. 15, no. 2, pp. 296–301, 2009.

[150] T. Skaali, S. D. Fossa, S. Andersson et al., “Self-reported cognitive problems in testicular cancer patients: relation to neuropsychological performance, fatigue, and psychological distress,” *Journal of Psychosomatic Research*, vol. 70, no. 5, pp. 403–410, 2011.

[151] J. Skoogh, G. Steineck, U. Stiernert et al., “Testicular-cancer survivors experience compromised language following chemotherapy: findings in a Swedish population-based study 3-26 years after treatment,” *Acta Oncologica*, vol. 51, no. 2, pp. 185–197, 2012.

[152] J. S. Wefel, D. J. Vidrine, S. K. Marani et al., “A prospective study of cognitive function in men with non-seminomatous germ cell tumors,” *Psycho-Oncology*, vol. 23, no. 6, pp. 626–633, 2014.

[153] A. A. Dahl, C. F. Haaland, A. Mykletun et al., “Study of anxiety disorder and depression in long-term survivors of testicular cancer,” *Journal of Clinical Oncology*, vol. 23, no. 10, pp. 2389–2395, 2005.

[154] S. Vehling, A. Mehnert, M. Hartmann, C. Oing, C. Bokemeyer, and K. Oechslle, “Anxiety and depression in long-term testicular germ cell tumor survivors,” *General Hospital Psychiatry*, vol. 38, pp. 21–25, 2016.

[155] E. H. Shinn, K. Basen-Engquist, B. Thornton, P. E. Spiess, and L. Pisters, “Health behaviors and depressive symptoms in testicular cancer survivors,” *Urology*, vol. 69, no. 4, pp. 748–753, 2007.

[156] A. B. Smith, P. Butow, I. Olver et al., “The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study,” *Journal of Cancer Survivorship*, vol. 10, no. 2, pp. 223–233, 2016.

[157] J. E. Bower, “Cancer-related fatigue—mechanisms, risk factors, and treatments,” *Nature Reviews Clinical Oncology*, vol. 11, no. 10, pp. 597–609, 2014.

[158] L. J. Orre, S. D. Fossa, R. Murison et al., “Chronic cancer-related fatigue in long-term survivors of testicular cancer,” *Journal of Psychosomatic Research*, vol. 64, no. 4, pp. 363–371, 2008.

[159] M. Sprauten, H. S. Haugnes, M. Brydoy et al., “Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors,” *Annals of Oncology*, vol. 26, no. 10, pp. 2133–2140, 2015.

[160] K. M. Mustian, C. M. Alfano, C. Heckler et al., “Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis,” *JAMA Oncology*, vol. 3, no. 7, pp. 961–968, 2017.

[161] L. B. Travis, C. Beard, J. M. Allan et al., “Testicular cancer survivorship: research strategies and recommendations,” *Journal of the National Cancer Institute*, vol. 102, no. 15, pp. 1114–1130, 2010.

[162] K. D. Miller, R. L. Siegel, C. C. Lin et al., “Cancer treatment of high blood cholesterol in adults (adult treatment panel III),” *Journal of the American Medical Association*, vol. 285, no. 19, pp. 2486–2497, 2001.
[164] L. Richiardi, G. Scelo, P. Boffetta et al., “Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries,” *International Journal of Cancer*, vol. 120, no. 3, pp. 623–631, 2007.

[165] K. Hemminki, H. Liu, and J. Sundquist, “Second cancers after testicular cancer diagnosed after 1980 in Sweden,” *Annals of Oncology*, vol. 21, no. 7, pp. 1546–1551, 2010.

[166] I. M. Ventry and B. E. Weinstein, “The hearing handicap inventory for the elderly: a new tool,” *Ear and Hearing*, vol. 3, no. 3, pp. 128–134, 1982.

[167] European Organisation for Research and Treatment of Cancer, *First EORTC Cancer Survivorship Summit*, Vol. 12, European Journal of Cancer Supplements, Brussels, Belgium, June 2014.

[168] J. Oldenburg, S. D. Fossa, and A. A. Dahl, “Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors,” *Quality of Life Research*, vol. 15, no. 5, pp. 791–800, 2006.

[169] L. B. Travis, “Therapy-associated solid tumors,” *Acta Oncologica*, vol. 41, no. 4, pp. 323–333, 2002.